[Genomic damage, adaptive response induction in blood lymphocytes at the prostate cancer patients. Connection with the tumour radiotherapy efficiency].
On the blood lymphocytes of prostate cancer (PCa) patients before and during radiotherapy: DNA damage by DNA commet assay (DNA double strand breaks - DSB); the frequency of cells with micronuclei (MN) with cytokinetic cytochalasin block; the adaptive response induction by the additional irradiation of PHA stimulated lymphocytes in the doses of 0.05 and 1.0 Gy 24 h and 48 h after stimulation were studied. Changes of these parameters with the decreasing of prostate specific antigen (PSA) have been compared. PSA decreasing is an adequate of the radiotherapy efficiency. It was shown that in oncological patients the DSB level and the frequency of cells with MN have been increased. During radiotherapy (in 3 months) the DNA DSB level and the frequency of cells with MN is enhancing. The degree and direction change of these parameters coincide. It was discovered the significant correlations between the enhancing of DNA DSB level and the cell frequency with MN during therapy and degree of the PSA level decreasing. Then it was shown that when the cell frequency with MN before treatment is higher the radiotherapy efficiency is worse. These results can have great significance for the evaluation of the prognosis of the treatment efficiency. The investigation of lymphocytes for the adaptive response ability has shown that in the patients with the pronounced adaptive response before radiotherapy the decrease of PSA level during treatment was not significant (in mean 3.5-3.6 ng/ml); when the adaptive response is absent or the phenomenon of enhanced radiosensitivity was observed the PSA level (in the most cases) was decreased very essential (in mean 0.07 ng/ml). We can suppose that prognosis of the treatment efficiency of the prostate cancer patients with the pronounced adaptive response in blood lymphocytes will be worse.
I I
II
Pelevina
A V
AV
Aleshchenko
M M
MM
Antoshchina
O V
OV
Kudriashova
E Iu
EIu
Lizunova
N G
NG
Minaeva
A N
AN
Osipov
E M
EM
Parshkov
N I
NI
Riabchenko
P V
PV
Sviridov
L P
LP
Semenova
A M
AM
Serebrianyĭ
D000222:Adaptation, Physiological / Q000235:genetics / Q000528:radiation effects*; D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects*; D002467:Cell Nucleus / Q000473:pathology; D003572:Cytochalasins / Q000494:pharmacology; D053903:DNA Breaks, Double-Stranded; D004307:Dose-Response Relationship, Radiation; D005819:Genetic Markers; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects*; D008297:Male; D015162:Micronucleus Tests; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
D003572:Cytochalasins; D005819:Genetic Markers; D007457:Iodine Radioisotopes; C031218:cytochalasin A